Cart
sales@molnova.com
Cucurbitacin IIb
CAS No. 50298-90-3
Cucurbitacin IIb( —— )
Catalog No. M18669 CAS No. 50298-90-3
Cucurbitacin IIb is one of the major active compounds in Hemsleyadine tablets which have been used for clinical treatment of bacillary dysentery, enteritis and acute tonsilitis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 240 | In Stock |
|
| 5MG | 208 | In Stock |
|
| 10MG | 359 | In Stock |
|
| 25MG | 592 | In Stock |
|
| 50MG | 820 | In Stock |
|
| 100MG | 1097 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCucurbitacin IIb
-
NoteResearch use only, not for human use.
-
Brief DescriptionCucurbitacin IIb is one of the major active compounds in Hemsleyadine tablets which have been used for clinical treatment of bacillary dysentery, enteritis and acute tonsilitis.
-
DescriptionCucurbitacin IIb is one of the major active compounds in Hemsleyadine tablets which have been used for clinical treatment of bacillary dysentery, enteritis and acute tonsilitis. Cucurbitacin IIb exhibits its anti-inflammatory activity through modulating multiple cellular behaviors and signaling pathways, leading to the suppression of the adaptive immune response.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research AreaInflammation/Immunology
-
Indication——
Chemical Information
-
CAS Number50298-90-3
-
Formula Weight520.7
-
Molecular FormulaC30H48O7
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (192.05 mM)
-
SMILESCC1(C(C(CC2C1=CCC3C2(C(=O)CC4(C3(CC(C4C(C)(C(=O)CCC(C)(C)O)O)O)C)C)C)O)O)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Cimifugin beta-D-glu...
Prim-O-glucosylcimifugin can inhibit the proliferation of SMC(smooth muscle cell) stimulated by TNF-alpha, increase the proportion of G0/G1 phase.
-
MRT-2359
MRT-2359 is a potent and orally available GSPT1 reducer with antitumour activity.MRT-2359 inhibits the growth of drug-resistant non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cells.MRT-2359 exhibits preferential activity in MYC-driven cell lines.
-
Matairesinol
Matairesinol has radical and superoxide scavenging activities; it also has anti-angiogenic activity by suppressing mROS signaling , can decrease hypoxia-inducible factor-1α± in hypoxic HeLa cells.
